HRT Benefits: What the Evidence Supports and What It Doesn't
Hormone therapy is the most effective treatment for hot flashes, night sweats and vaginal symptoms of menopause, and it prevents bone loss and fracture. For healthy women with bothersome symptoms who are under 60 or within 10 years of menopause, benefits generally outweigh risks. It isn't recommended for preventing dementia or other chronic disease.
Most coverage of hormone therapy leads with risk, which makes sense after the headlines of the early 2000s. But the same large trials that measured the risks also measured the benefits, and the expert statements built on them are surprisingly specific about both. Here's the benefit side, with the same honesty about where it stops.
What does HRT treat best?
Menopause symptoms themselves — above all hot flashes and night sweats, and the vaginal and urinary changes that come with falling estrogen. On these, the leading US menopause society doesn't hedge: nothing else it reviews works as well, which is why it's the first treatment many clinicians discuss.
If hot flashes are your main reason for considering it, our hot flashes guide compares hormone therapy with the non-hormonal options that also have strong evidence. For vaginal dryness alone, low-dose vaginal estrogen is often enough — see our vaginal estrogen guide.
Does HRT protect your bones?
Yes, and this is one of the best-established benefits. Bone loss speeds up around menopause, and hormone therapy slows it. This isn't only an observational impression: it has been shown in randomized trials, including the large Women's Health Initiative trials that are better known for their findings on risk.
What happens after stopping is worth knowing too. The NAMS statement notes that "discontinuing hormone therapy results in rapid bone loss; however, no excess in fractures was seen in the WHI after discontinuation." In the WHI itself, the hip-fracture reduction weakened after treatment ended, but in the estrogen-plus-progestin trial a significant benefit was still seen at 13 years of cumulative follow-up (HR 0.81; 95% CI, 0.68–0.97). For the wider picture on bone health, see our osteoporosis guide.
Does the age you start HRT change the benefits?
A great deal. This is the most important nuance in the whole topic. The balance of benefit and risk looks quite different for a woman of 52 than for a woman of 72, which is why the age of the women studied in the early trials shaped so much of the fear around hormone therapy.
The Women's Health Initiative shows the same pattern in absolute numbers. Measured by its global index of serious outcomes, estrogen alone was linked to 19 fewer adverse events per 10,000 women per year at ages 50–59, but 51 excess events at ages 70–79. Estrogen plus progestin ranged from 12 excess events per 10,000 women per year at 50–59 to 38 at 70–79. Starting later carries more risk; starting closer to menopause shifts the balance toward benefit.
Do the benefits differ between estrogen alone and estrogen with progestin?
Yes, and the difference is one of the clearer findings from the Women's Health Initiative. Women with a uterus need a progestogen alongside estrogen to protect the uterine lining, while women who've had a hysterectomy can take estrogen alone, and the two trials came out differently on several outcomes.
These trials used one specific older formulation (conjugated equine estrogens, with medroxyprogesterone acetate in the combined arm), so the numbers don't automatically apply to every product prescribed today. Which type you're offered depends on whether you still have a uterus, because a progestogen is needed to protect the lining; the trials simply show that the two regimens don't carry the same balance of benefit and risk.
What about diabetes, colon cancer and lifespan?
Here the evidence is real but more mixed, and worth reading carefully. Some of it comes from randomized trials, some only from observational studies, which can't fully separate the effect of hormones from the kind of women who choose to take them.
- Diabetes: fewer cases of diabetes were among the benefits seen during the WHI estrogen-plus-progestin trial, and the NAMS statement lists reduced absolute risk of diabetes in women under 60.
- Colorectal cancer: in the WHI estrogen-plus-progestin trial, fewer colorectal cancers were diagnosed during treatment (HR 0.62; 95% CI, 0.43–0.89), but the cancers found were at a more advanced stage, and estrogen alone had no effect (HR 1.15). NAMS adds that observational studies "generally support a reduced risk of colorectal cancer in current hormone therapy users," with no benefit from past use, while noting confounding may contribute.
- Lifespan: over 18 years of follow-up, hormone therapy in the WHI trials "was not associated with risk of all-cause, cardiovascular, or cancer mortality."
What isn't HRT for?
Preventing chronic disease on its own. This is where the evidence draws a firm line, and it's worth knowing before anyone suggests hormones as a general health or anti-aging measure. The benefits above are real, but they're the reason to treat symptoms and protect bone, not a reason to take hormones without them.
Two clear limits. The North American Menopause Society states that "hormone therapy is not recommended at any age to prevent or treat a decline in cognitive function or dementia," noting that in the WHI Memory Study, estrogen plus progestin started after 65 increased dementia risk, with "an additional 23 cases per 10,000 person-years," while estrogen alone did not significantly increase it. And the WHI investigators concluded their findings "do not support use of this therapy for chronic disease prevention, although it is appropriate for symptom management in some women."
For everyday side effects and warning signs, see our HRT side effects guide; the serious long-term risks, like blood clots and breast cancer, are covered in our HRT guide. If you're choosing between forms, our estrogen patch article explains why the route can change some risks.
Where to go from here
If you're weighing hormone therapy, read this alongside our HRT side effects guide. If menopause came before 45, our early menopause article explains why the recommendation is stronger for that group. And if your current clinician isn't comfortable discussing hormone therapy, our guide to finding a menopause specialist can help.
For how all of this fits into the bigger picture of midlife sleep, start at the complete perimenopause and menopause sleep guide.
Key takeaways
- HRT is the most effective treatment for hot flashes, night sweats and the genitourinary syndrome of menopause, and it's FDA-approved as first-line therapy for moderate to severe hot flashes.
- It prevents bone loss and fracture, shown in randomized trials. Bone density falls fairly quickly after stopping, though the WHI found no excess in fractures afterward.
- Timing matters most: under 60 or within 10 years of menopause, NAMS calls the benefit-risk ratio favorable, and for women under 60 it lists lower absolute risks of death, fracture and diabetes.
- No increase in long-term mortality: 27.1% vs 27.6% over 18 years in the WHI trials (HR 0.99).
- The colorectal picture is mixed: fewer cases with estrogen plus progestin in the WHI trial, but found at a later stage, and no effect with estrogen alone.
- It isn't for preventing dementia or chronic disease; estrogen plus progestin started after 65 increased dementia risk in the WHI Memory Study.
Frequently asked questions
What are the main benefits of HRT?
According to The North American Menopause Society's 2022 position statement, hormone therapy is the most effective treatment for hot flashes, night sweats and the genitourinary syndrome of menopause, and it has been shown to prevent bone loss and fracture.
Does HRT protect against osteoporosis?
Yes. The North American Menopause Society states that randomized trials show hormone therapy decreases fracture risk, and the Women's Health Initiative trials found fewer hip fractures during treatment. Hormone therapy is government-approved for preventing osteoporosis.
Does the age you start HRT change the benefits?
Yes. The North American Menopause Society says the benefit-risk balance is favorable for women younger than 60 or within 10 years of menopause onset. In women under 60, its statement lists reduced absolute risks of all-cause mortality, fracture and diabetes, and of breast cancer with estrogen alone.
Does HRT prevent dementia or heart disease?
It isn't recommended for that. The North American Menopause Society says hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia, and the Women's Health Initiative investigators concluded their findings do not support using it for chronic disease prevention.
Does HRT increase the risk of dying early?
Not in the long-term Women's Health Initiative follow-up. Over 18 years, all-cause mortality was 27.1% with hormone therapy and 27.6% with placebo (hazard ratio 0.99), with no increase in cardiovascular or cancer deaths.
Sources cited
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. menopause.org (full text, PDF)
- Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. pubmed.ncbi.nlm.nih.gov
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. pubmed.ncbi.nlm.nih.gov
How this article was checked
The North American Menopause Society statement was read in its full published text, and every quote from it appears as written there. The Women's Health Initiative figures come from the two Manson et al. papers (the 2013 report read in full text), including the age-specific absolute risks and the investigators' own conclusion against using hormone therapy for chronic disease prevention. An independent fact-check caught real errors in an earlier draft, now fixed: it said the bone benefit fades after stopping (the WHI found no excess in fractures afterward), called the colorectal finding observational-only (the WHI combined-therapy trial also showed fewer cases), and gave the wrong reason for why the type of therapy depends on having a uterus.
It has not been reviewed by a clinician. Ellen Hayes is a researcher and writer, not a doctor, and nothing here is a diagnosis or a substitute for being seen by one.
Ellen Hayes
Health & Wellness Writer and Researcher
Hi — I'm Ellen. I wanted one place that lays out the benefit side as carefully as the risk side usually gets. The part I'd underline is timing: the same treatment looks very different at 52 than at 72, and the trial behind most of the scary headlines enrolled women who were, on average, in their 60s.
I'm not a doctor. I'm not an expert — and I'm never going to talk down to you like one. I'm a woman in the middle of perimenopause who got tired of vague answers, started reading the actual research, and writes it down here in plain English, the way I'd explain it to a friend over coffee. More about Ellen →